Safety of Patisaran LNP | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34233 of 34737  at  3/28/2018 10:18:13 AM  by

egomaniakos


Safety of Patisaran LNP

For those looking in on LNP safety here for gene therapy is some safety validation from our old LNPs used in ALNY Patisaran:

In the Global OLE Study, patients were treated with patisiran (overall mean
12 months) for an additional 11 or 21 months (APOLLO patisiran and Phase 2
patisiran, respectively) or newly treated for 10 months (APOLLO placebo), representing 211 patient-years and 3,506 doses.

Twenty-five patients, originally in the Phase 2 study, have now received patisiran for up to four years.

As of December 1, 2017, 25 patients (11.8 percent) have received over 269 infusions at home. One patient had a mild IRR at home that did not require treatment.

The safety profile of all patients in the Global OLE (N=211) was consistent with that observed in APOLLO, with infusion-related reactions (IRRs, 10.4 percent) representing the most common drug-related AE. There were two patients with reports of drug-related SAEs; one with phlebitis secondary to drug extravasation at the infusion site, cellulitis and hypotension, and one with abdominal discomfort, with the latter resulting in withdrawal from study.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 287
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...